Quick Answer
Protagonist Therapeutics, Inc reported Stockholders Equity of $614.71 million for fiscal year 2025.
Protagonist Therapeutics, Inc Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $614.71M | -9.0% |
| 2024 | $675.29M | +100.6% |
| 2023 | $336.68M | +56.2% |
| 2022 | $215.61M | -28.1% |
| 2021 | $300.02M | +7.3% |
| 2020 | $279.61M | +249.7% |
| 2019 | $79.96M | -28.9% |
| 2018 | $112.52M | -6.7% |
| 2017 | $120.63M | +37.8% |
| 2016 | $87.56M | +419.5% |
| 2015 | -$27.40M | -117.1% |
| 2014 | -$12.62M | -805.4% |
| 2013 | -$1.39M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $645.44M | +21.3% | -3.4% |
| June 30, 2025 | $668.02M | +23.4% | -3.1% |
| March 31, 2025 | $689.05M | +22.9% | +2.0% |
| December 31, 2024 | $675.29M | +100.6% | +27.0% |
| September 30, 2024 | $531.91M | +76.0% | -1.7% |
| June 30, 2024 | $541.32M | +84.1% | -3.4% |
| March 31, 2024 | $560.44M | +159.3% | +66.5% |
| December 31, 2023 | $336.68M | +56.2% | +11.4% |
- Protagonist Therapeutics, Inc showed a decrease of -9.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2013–2025 period, Protagonist Therapeutics, Inc’s stockholders equity has grown by 44196.6% (from -$1.39 million to $614.71 million).
- The most recent figure is from Protagonist Therapeutics, Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: